Acutaas Chemicals Q1 FY26 Concall Decoded: PAT triples to ₹44 Cr, but Specialty Chem still flatlining

1. Opening Hook

Imagine rebranding yourself with a shiny new name (Acutaas from Ami) and then showing up with a quarterly profit that’s 3x. Not bad for an identity makeover. Pharma intermediates came charging with 23% growth, but specialty chemicals? More like that backbencher who copies homework but never improves. The management, of course, still promises 25% growth for FY26 with better margins. Will they deliver or is this another “chemist’s cocktail of hope”? Read on—the semiconductor JV twist comes later.

2. At a Glance

• Revenue ₹207 Cr (+17.3% YoY) – Mostly pharma intermediates doing the heavy lifting.
• Gross Margin 53.2% (+1,117 bps) – Optimization + product mix = magic potion.
• EBITDA ₹50.9 Cr (+72.4% YoY) – Operating leverage finally showed up.
• PAT ₹44 Cr (3x YoY) – Forex gains spiked the punch bowl.
• Cash ₹270 Cr – Plenty of dry powder for capex.
• Capex ₹69 Cr this quarter; FY26 target ₹250 Cr – Heavy bets on electrolytes and semicon.

3. Management’s Key Commentary

“Pharma intermediates grew 23% YoY; CDMO projects on track.”
(Translation: Pharma is still our sugar daddy.)

“Specialty chemicals revenue flattish due to Baba Fine Chemicals.”
(Translation: The semiconductor bet isn’t paying yet, patience required.)

“Gross margins at 53.2%, thanks to cost cuts and product mix.”
(Translation: Squeezed suppliers, shifted mix—classic desi jugaad.)

“Electrolyte additive capex of ₹177 Cr; contracts signed.”
(Translation: Betting big on EV batteries, but revenue comes only FY27.)

“JV in Korea for semiconductor materials, 75% stake.”
(Translation: We’ll sell chip chemicals to Korea, since India has none.)

“25% revenue growth for FY26 is intact with better margins.”
(Translation: Quarter was good, don’t question us till Q4.)

4. Numbers Decoded